journal article·2021-06-16Open access

Polyoxometalates as Effective Nano-inhibitors of Amyloid Aggregation of Pro-inflammatory S100A9 Protein Involved in Neurodegenerative Diseases

Himanshu Chaudhary, Igor A. Iashchishyn, Nina V. Romanova, Mark A. Rambaran, Greta Musteikyte, Vytautas Smirnovas, Michael Holmboe, C. André Ohlin, Željko M. Svedružić, Ludmilla A. Morozova-Roche

ACS Applied Materials & Interfaces· Volume 13· Issue 23

Abstract

Pro-inflammatory and amyloidogenic S100A9 protein is central to the amyloid-neuroinflammatory cascade in neurodegenerative diseases. Polyoxometalates (POMs) constitute a diverse group of nanomaterials, which showed potency in amyloid inhibition. Here, we have demonstrated that two selected nanosized niobium POMs, Nb10 and TiNb9, can act as potent inhibitors of S100A9 amyloid assembly. Kinetics analysis based on ThT fluorescence experiments showed that addition of either Nb10 or TiNb9 reduces the S100A9 amyloid formation rate and amyloid quantity. Atomic force microscopy imaging demonstrated the complete absence of long S100A9 amyloid fibrils at increasing concentrations of either POM and the presence of only round-shaped and slightly elongated aggregates. Molecular dynamics simulation revealed that both Nb10 and TiNb9 bind to native S100A9 homo-dimer by forming ionic interactions with the positively charged Lys residue-rich patches on the protein surface. The acrylamide quenching of intrinsic fluorescence showed that POM binding does not perturb the Trp 88 environment. The far and near UV circular dichroism revealed no large-scale perturbation of S100A9 secondary and tertiary structures upon POM binding. These indicate that POM binding involves only local conformational changes in the binding sites. By using intrinsic and 8-anilino-1-naphthalene sulfonate fluorescence titration experiments, we found that POMs bind to S100A9 with a Kd of ca. 2.5 μM. We suggest that the region, including Lys 50 to Lys 54 and characterized by high amyloid propensity, could be the key sequences involved in S1009 amyloid self-assembly. The inhibition and complete hindering of S100A9 amyloid pathways may be used in the therapeutic applications targeting the amyloid-neuroinflammatory cascade in neurodegenerative diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Alzheimer's disease research and treatments · S100 Proteins and Annexins · Cholinesterase and Neurodegenerative Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Biochemistry and Biophysics, Umeå University, Umeå 90187, Sweden

Department of Chemistry, Umeå University, 90187 Umeå, Sweden

Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius LT-10257, Lithuania

Department of Biotechnology, University of Rijeka, Rijeka HR 51000, Croatia

Funding

Vetenskapsr??det · Medicinska Forskningsr??det · Insamlingsstiftelsen · Forskningsstrategiska medel, Medical Faculty, Ume?? University · Swedish National Science Foundation · Kempe foundations · Demensfonden

References (79)

Show source-provided references
1. 10.1126/science.107299410.1126/science.1072994 ↗
2. 10.1038/416507a10.1038/416507a ↗
3. 10.1016/j.jalz.2007.04.38110.1016/j.jalz.2007.04.381 ↗
4. 10.1007/978-1-4939-7704-8_110.1007/978-1-4939-7704-8_1 ↗
5. 10.1021/acschemneuro.8b0016610.1021/acschemneuro.8b00166 ↗
6. 10.1039/C8CC03235A10.1039/C8CC03235A ↗
7. 10.1002/adma.20130121010.1002/adma.201301210 ↗
8. 10.1007/s11051-011-0276-410.1007/s11051-011-0276-4 ↗
9. 10.1002/anie.20180386810.1002/anie.201803868 ↗
10. 10.1038/ncomms442210.1038/ncomms4422 ↗
11. 10.1021/ja001809e10.1021/ja001809e ↗
12. 10.1039/c1dt10435g10.1039/c1dt10435g ↗
13. 10.1016/j.ica.2008.06.00610.1016/j.ica.2008.06.006 ↗
14. 10.1107/S056774087700790010.1107/S0567740877007900 ↗
15. 10.1039/B900465C10.1039/B900465C ↗
16. 10.1007/s00011-018-1173-410.1007/s00011-018-1173-4 ↗
17. 10.1182/blood-2016-09-73800510.1182/blood-2016-09-738005 ↗
18. 10.1001/jamainternmed.2013.653610.1001/jamainternmed.2013.6536 ↗
19. 10.1523/JNEUROSCI.1504-12.201210.1523/JNEUROSCI.1504-12.2012 ↗
20. 10.3390/ijms1303289310.3390/ijms13032893 ↗
21. 10.1007/s00401990017210.1007/s004019900172 ↗
22. 10.1038/s41598-018-31141-x10.1038/s41598-018-31141-x ↗
23. 10.1186/s12974-018-1210-910.1186/s12974-018-1210-9 ↗
24. 10.1007/s00401005093810.1007/s004010050938 ↗
25. 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-710.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7 ↗
26. 10.1016/j.cmet.2013.04.00110.1016/j.cmet.2013.04.001 ↗
27. 10.1016/j.ijcard.2011.01.08210.1016/j.ijcard.2011.01.082 ↗
28. 10.1038/srep0121510.1038/srep01215 ↗
29. 10.1007/s00401-013-1208-410.1007/s00401-013-1208-4 ↗
30. 10.1371/journal.pone.000556210.1371/journal.pone.0005562 ↗
31. 10.1371/journal.pone.000884010.1371/journal.pone.0008840 ↗
32. 10.1039/C9SC05905A10.1039/C9SC05905A ↗
33. 10.1021/acschemneuro.5b0026510.1021/acschemneuro.5b00265 ↗
34. 10.1002/ejic.20190075010.1002/ejic.201900750 ↗
35. 10.1021/ja100490n10.1021/ja100490n ↗
36. 10.1016/j.bbamcr.2006.08.02810.1016/j.bbamcr.2006.08.028 ↗
37. 10.3109/1350612950903188110.3109/13506129509031881 ↗
38. 10.1007/BF0139151610.1007/BF01391516 ↗
39. 10.1002/chem.20090241510.1002/chem.200902415 ↗
40. 10.1038/ncomms328510.1038/ncomms3285 ↗
41. 10.1021/j150440a00410.1021/j150440a004 ↗
42. 10.1016/j.ab.2014.07.01110.1016/j.ab.2014.07.011 ↗
43. 10.1073/pnas.18134239810.1073/pnas.181342398 ↗
44. 10.1016/j.bbapap.2016.08.00810.1016/j.bbapap.2016.08.008 ↗
45. 10.1002/jcc.2008410.1002/jcc.20084 ↗
46. 10.1021/cr990400910.1021/cr9904009 ↗
47. 10.1063/1.47852210.1063/1.478522 ↗
48. 10.1039/b508541a10.1039/b508541a ↗
49. 10.1002/jcc.2326610.1002/jcc.23266 ↗
50. 10.1371/journal.pone.017441010.1371/journal.pone.0174410 ↗
51. 10.1016/0263-7855(96)00018-510.1016/0263-7855(96)00018-5 ↗
52. 10.1093/bioinformatics/btl46110.1093/bioinformatics/btl461 ↗
53. 10.1021/acschemneuro.7b0025110.1021/acschemneuro.7b00251 ↗
54. 10.1021/acschembio.9b0039410.1021/acschembio.9b00394 ↗
55. 10.1016/0076-6879(86)30013-210.1016/0076-6879(86)30013-2 ↗
56. 10.1021/bi00520a00310.1021/bi00520a003 ↗
57. 10.1021/ar100110d10.1021/ar100110d ↗
58. 10.1016/S0006-3495(98)77799-910.1016/S0006-3495(98)77799-9 ↗
59. 10.3389/fnagi.2018.0002110.3389/fnagi.2018.00021 ↗
60. 10.1038/srep0813910.1038/srep08139 ↗
61. 10.1021/acs.langmuir.8b0038810.1021/acs.langmuir.8b00388 ↗
62. 10.1038/srep4085910.1038/srep40859 ↗
63. 10.1007/s13311-012-0105-110.1007/s13311-012-0105-1 ↗
64. 10.1186/s12915-017-0390-610.1186/s12915-017-0390-6 ↗
65. 10.1371/journal.pone.002723010.1371/journal.pone.0027230 ↗
66. 10.1016/j.bbapap.2009.09.00310.1016/j.bbapap.2009.09.003 ↗
67. 10.1016/j.biopha.2004.11.00810.1016/j.biopha.2004.11.008 ↗
68. 10.1042/bj319061910.1042/bj3190619 ↗
69. 10.1016/j.jinorgbio.2009.05.00210.1016/j.jinorgbio.2009.05.002 ↗
70. 10.1016/j.chembiol.2008.05.01810.1016/j.chembiol.2008.05.018 ↗
71. 10.1002/anie.20050010810.1002/anie.200500108 ↗
72. 10.1039/C7DT00894E10.1039/C7DT00894E ↗
73. 10.3390/inorganics302016010.3390/inorganics3020160 ↗
74. 10.1016/j.apsusc.2010.10.02110.1016/j.apsusc.2010.10.021 ↗
75. 10.1021/acsbiomaterials.9b0049310.1021/acsbiomaterials.9b00493 ↗
76. 10.1007/s10856-014-5153-010.1007/s10856-014-5153-0 ↗
77. 10.1177/095441192096085410.1177/0954411920960854 ↗
78. 10.1016/j.colsurfa.2010.11.06810.1016/j.colsurfa.2010.11.068 ↗
79. 10.1002/anie.20100706710.1002/anie.201007067 ↗